Skip to the content
Neurodexlogo darklogo light
  • Home
  • About Us
    • Our Team
    • Our Lab
  • Our Tech
    • ExoSort Platform
    • Our Projects
    • Publications
    • Pipeline
  • Services
    • Neurodiagnostic Platform
    • Research Services
    • ⁠Pre-Clinical Services
    • Clinical Trial Services
  • NeuroDex News
  • Contact Us
Search
Neurodex
  • Home
  • About Us
    • Our Team
    • Our Lab
  • Our Tech
    • ExoSort Platform
    • Our Projects
    • Publications
    • Pipeline
  • Services
    • Neurodiagnostic Platform
    • Research Services
    • ⁠Pre-Clinical Services
    • Clinical Trial Services
  • NeuroDex News
  • Contact Us
Home2023
Exosomes: The Unseen Players in Neurodegenerative Diseases
Biotech Blog

Exosomes: The Unseen Players in Neurodegenerative Diseases

ervin@a2z.rs
December 18, 2023
Promising Results from Athira Pharma's Fosgonimeton
Biotech Blog

Promising Results from Athira Pharma’s Fosgonimeton

ervin@a2z.rs
December 13, 2023
NeuroDex Announces Second Award from The Michael J. Fox Foundation
NeuroDex News

NeuroDex Announces Second Award from The Michael J. Fox Foundation

Ariella Weihs
November 3, 2023
Neurodex to Participate in 2nd Annual AAEV Meeting: Exploring the Potential of Extracellular Vesicles
NeuroDex News

Neurodex to Participate in 2nd Annual AAEV Meeting: Exploring the Potential of Extracellular Vesicles

Ariella Weihs
October 26, 2023
NeuroDex’s Chief Scientific Officer, Dr. Erez Eitan to Speak on Groundbreaking Biomarker Research at ISEV Workshop
NeuroDex News

NeuroDex’s Chief Scientific Officer, Dr. Erez Eitan to Speak on Groundbreaking Biomarker Research at ISEV Workshop

Ariella Weihs
October 9, 2023
Canadian AI Technology Revolutionizes Early Detection of ALS
Biotech Blog

Groundbreaking Canadian AI Technology Revolutionizes Early Detection of ALS

ervin@a2z.rs
September 22, 2023
Nimbus Therapeutics
Biotech Blog

Nimbus Therapeutics Secures $210 Million Investment from GV, Google’s Investment Arm, for AI-Driven Drug Discovery

ervin@a2z.rs
September 8, 2023
CervoMed's Merger with EIP Pharma: Paving the Way for Brain Disease Treatments
Biotech Blog

CervoMed’s Merger with EIP Pharma: Paving the Way for Brain Disease Treatments

ervin@a2z.rs
August 17, 2023
Sunbird Bio and Glympse Bio Merge
Biotech Blog

Sunbird Bio and Glympse Bio Merge to Accelerate Development of Innovative Protein-Based Diagnostic Technologies

ervin@a2z.rs
August 10, 2023
Donanemab Results in Cognitive Decline in Alzheimer's Disease
Biotech Blog

Donanemab Shows Promising Results in Slowing Cognitive Decline in Alzheimer’s Disease

ervin@a2z.rs
July 17, 2023

Posts pagination

1 2
ervin@a2z.rs

principal scientist

TDP-43 in ALS & Neurodegeneration: Key Insights

ervin@a2z.rs
September 25, 2025

ALS Drug Development: A Comparative Analysis of Oral, Antioxidant, & Gene-Targeted Approaches

ervin@a2z.rs
September 17, 2025
Categories
Biotech Blog Explanation Material NeuroDex News
Follow us
w
We believe in open projects
View more

Contact Us

Company

NeuroDex Inc

  • 22 Strathmore Road
  • Natick, MA US 01760
  • info@neurodex.co
Informations
  • Terms & Conditions
  • Privacy Policy
  • FAQ Page
Resources
  • Explanation Material
  • NeuroDex News
  • Blog

© 2025 A2Z Solutions, All Rights Reserved

Back to top Drag
w
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}